XSTO
VIMIAN
Market cap1.85bUSD
Oct 07, Last price
34.95SEK
1D
-0.99%
1Q
14.97%
IPO
-60.28%
Name
Vimian Group AB
Chart & performance
P/E
52.61
P/S
3.87
EPS
0.06
Div yield, %
—
Shrs. gr., 5y
6.89%
Rev. gr., 5y
25.27%
Revenues
425m
+13.39%
Net income
31m
+69.19%
CFO
106m
+81.93%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets. Moreover, its VetFamily brand operates a membership-based platform that provides veterinary clinics with procurement services, tech-enabled operations including online marketing, education, and HR support, as well as a professional community. The company also supplies orthopedic implants to veterinarians and universities through its Movora brand. Established in 2020, Vimian Group is based in Stockholm, Sweden.
Related entities
Parent (2)
Fidelio Vet Holding AB
Berghamnen AB
Subsidiaries
Vimian FinCo AB
Headquarters & legal address
Riddargatan 19
Stockholm, AB 114 57
SE
Stockholm, AB 114 57
SE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||